Medical device specialist Next Biomedical jumped more than 10% early on the 10th. Buyers piled in on news that it signed an exclusive licensing agreement with Asahi Intecc, a Japan-based global medical device company.
As of 9:22 a.m., Next Biomedical was trading on the KOSDAQ market at 66,900 won, up 6,100 won (10.03%) from the previous session.
According to the Financial Supervisory Service's electronic disclosure system, Next Biomedical said after the market closed on the 9th that it signed an exclusive sales agreement in Japan with Asahi Intecc for the intravascular embolization-promoting implant "Nexsphere-F™." The contract period is five years after the product is listed for insurance reimbursement, and it will be renewed annually thereafter.
Next Biomedical is a corporations that generates revenue by directly exporting finished goods medical devices. Its flagship product, Nexsphere-F, has received product approvals from the Ministery of Food and Drug Safety, the European CE-MDD (Medical Devices Directive), and Health Canada. Post-marketing clinical trials are currently underway domestically and overseas.
Asahi Intecc is a corporations specializing in medical microcatheters and guidewires. Guidewires are essential in most endovascular interventions, and microcatheters are also key medical devices used in various embolization procedures, including musculoskeletal embolization and transarterial chemoembolization. The company currently supplies products to about 120 countries worldwide.